Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Fiche publication
Date publication
décembre 2023
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian, Dr JUNG Alain, Dr MARTIN Sophie, Dr BURGY Mickaël
Tous les auteurs :
Hélène C, Conrad O, Pflumio C, Borel C, Voegelin M, Bernard A, Schultz P, Onea MA, Jung A, Martin S, Burgy M
Lien Pubmed
Résumé
Immune checkpoint inhibitors of programmed cell death protein 1 (PD-1) represent a significant breakthrough in treating head and neck squamous cell carcinoma (HNSCC), with long-lasting responses and prolonged survival observed in first- and second-line therapy. However, this is observed in < 20% of patients and high primary/secondary resistance may occur. The primary objective of the identification of predictive factors for the response to anti-PD-1 immunotherapy in head and neck squamous cell carcinoma (IPRICE) study is to identify predictive factors of response to anti-PD-1 immunotherapy.
Mots clés
HNSCC tumour microenvironment, Head and neck squamous cell carcinoma, Immune response, Response biomarker, Spatial transcriptomic
Référence
BMC Cancer. 2023 12 8;23(1):1209